Drugs that contain Saxagliptin Hydrochloride
1. List of Onglyza drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| USRE44186 | ASTRAZENECA AB | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
Jul, 2023
(3 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7951400 | ASTRAZENECA AB | Coated tablet formulation and method |
Nov, 2028
(5 years from now) | |
Market Authorisation Date: 31 July, 2009
Treatment: Method for treating type ii diabetes by administering saxagliptin; Method for treating type ii diabetes mellitus by administering saxagliptin alone or in combination with insulin, metformin, a thiazol...
Dosage: TABLET;ORAL
ONGLYZA family patents
7
United States
3
Slovenia
3
Spain
3
European Union
2
Israel
2
Denmark
2
Hong Kong
2
Hungary
2
Argentina
2
Croatia
2
Portugal
2
Cyprus
2
Korea, Republic of
2
Poland
2
Taiwan, Province of China
2
RS
2
China
2
ME
1
South Africa
1
Mexico
1
Australia
1
Russia
1
Lithuania
1
Norway
1
Brazil
1
Malaysia
1
Peru
1
Georgia
1
Ukraine
1
Japan
1
Canada
1
New Zealand
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic